SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Solta Medical, Inc. - SLTM
NEW YORK, Dec. 16, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of Solta Medical, Inc. ("Solta" or the "Company") (NYSE: SLTM) (ISIN: US83438K1034) (CUSIP: 83438K103) concerning the proposed acquisition of Solta by Valeant Pharmaceuticals International, Inc.
The investigation concerns whether the Solta directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, Solta shareholders will receive $2.92 per share in cash for each share of Solta common stock. However, the Price to Total Assets and Revenue multiples are below the averages of comparable transactions.
Solta shareholders seeking more information about this acquisition are advised to contact Ofer Ganot at email@example.com or 212-661-1100, ext. 315.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.
Pomerantz Grossman Hufford Dahlstrom & Gross LLP
212-661-1100 ext. 315
SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP